IL248792B - hsp70 modulators and methods for their preparation and use - Google Patents
hsp70 modulators and methods for their preparation and useInfo
- Publication number
- IL248792B IL248792B IL248792A IL24879216A IL248792B IL 248792 B IL248792 B IL 248792B IL 248792 A IL248792 A IL 248792A IL 24879216 A IL24879216 A IL 24879216A IL 248792 B IL248792 B IL 248792B
- Authority
- IL
- Israel
- Prior art keywords
- making
- methods
- same
- hsp70
- modulators
- Prior art date
Links
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992838P | 2014-05-13 | 2014-05-13 | |
| PCT/US2015/030641 WO2015175707A1 (en) | 2014-05-13 | 2015-05-13 | Hsp70 modulators and methods for making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL248792A0 IL248792A0 (en) | 2017-01-31 |
| IL248792B true IL248792B (en) | 2020-01-30 |
Family
ID=53284541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL248792A IL248792B (en) | 2014-05-13 | 2016-11-07 | hsp70 modulators and methods for their preparation and use |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9878987B2 (OSRAM) |
| EP (1) | EP3143013B1 (OSRAM) |
| JP (1) | JP6607870B2 (OSRAM) |
| KR (1) | KR102461419B1 (OSRAM) |
| CN (1) | CN107074806B (OSRAM) |
| AU (1) | AU2015259173B2 (OSRAM) |
| BR (1) | BR112016026470A8 (OSRAM) |
| CA (1) | CA2948621A1 (OSRAM) |
| EA (1) | EA201692155A1 (OSRAM) |
| ES (1) | ES2774975T3 (OSRAM) |
| IL (1) | IL248792B (OSRAM) |
| MX (1) | MX375924B (OSRAM) |
| PH (1) | PH12016502244A1 (OSRAM) |
| SG (1) | SG11201609336PA (OSRAM) |
| TW (1) | TWI699204B (OSRAM) |
| WO (1) | WO2015175707A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108752280A (zh) | 2009-08-17 | 2018-11-06 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
| AU2015259173B2 (en) * | 2014-05-13 | 2019-09-05 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
| BR112018006572A2 (pt) | 2015-10-05 | 2018-10-09 | Memorial Sloan Kettering Cancer Center | terapia de combinação racional para o tratamento de câncer |
| AU2019239658A1 (en) * | 2018-03-21 | 2020-11-12 | Suzhou Puhe BioPharma Co., Ltd. | SHP2 inhibitors and uses thereof |
| EP3845533A4 (en) | 2018-08-27 | 2022-04-27 | Sumitomo Dainippon Pharma Co., Ltd. | OPTICALLY ACTIVE AZABICYCLIC DERIVATIVE |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB951432A (en) | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| GB990857A (en) | 1961-10-13 | 1965-05-05 | Wellcome Found | 1,3-diazaphenothiazines |
| US3248393A (en) | 1960-06-23 | 1966-04-26 | Burroughs Wellcome Co | 1, 3-diazaphenothiazines and method |
| US4039543A (en) | 1974-12-24 | 1977-08-02 | Hoffmann-La Roche Inc. | Benzylpyrimidines |
| CH605828A5 (OSRAM) | 1974-12-24 | 1978-10-13 | Hoffmann La Roche | |
| US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| DE3311703A1 (de) | 1983-03-30 | 1984-10-04 | Bayer Ag, 5090 Leverkusen | Harnstoffderivate |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| KR960704855A (ko) | 1993-10-12 | 1996-10-09 | 돈 엠. 커. | 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof) |
| DE4423098A1 (de) | 1994-07-01 | 1996-01-04 | Hoechst Ag | Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JPH09236070A (ja) | 1996-02-29 | 1997-09-09 | Denso Corp | スタータ |
| US5707930A (en) | 1996-09-16 | 1998-01-13 | Zeneca Limited | 4-cycloalkyl-5-substituted pyrimidine compounds useful as crop protection agents |
| DE60136731D1 (de) | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | Pyrazine derivate als tyrosin kinase modulatoren |
| KR100819668B1 (ko) | 2000-12-18 | 2008-04-04 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘-설퍼아마이드 |
| US6423720B1 (en) | 2001-02-01 | 2002-07-23 | Duquesne University Of The Holy Ghost | Pyrimidine compounds and methods for making and using the same |
| US7501429B2 (en) | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| AU2004220234C1 (en) | 2003-02-13 | 2013-01-17 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
| ES2559779T3 (es) | 2003-08-29 | 2016-02-15 | Vernalis (R&D) Limited | Compuestos de pirimidotiofeno |
| US20050070712A1 (en) | 2003-09-26 | 2005-03-31 | Christi Kosogof | Pyrimidine derivatives as ghrelin receptor modulators |
| CA2557372C (en) | 2004-03-05 | 2013-01-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| WO2005110416A2 (en) | 2004-05-08 | 2005-11-24 | Neurogen Corporation | 4,5-disubstituted-2-aryl pyrimidines |
| CA2600531A1 (en) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
| CA2620129C (en) * | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| US20070259820A1 (en) | 2006-05-03 | 2007-11-08 | The Regents Of The University Of Michigan | Methods and reagents for activating heat shock protein 70 |
| JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| US20080124407A1 (en) | 2006-10-10 | 2008-05-29 | University Of Washington | Inhibiting cyp3a4 induction |
| PL2091918T3 (pl) | 2006-12-08 | 2015-02-27 | Novartis Ag | Związki i kompozycje jako inhibitory kinazy białkowej |
| WO2008092199A1 (en) | 2007-01-31 | 2008-08-07 | Cytopia Research Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| TW200911240A (en) | 2007-06-11 | 2009-03-16 | Kyowa Hakko Kogyo Kk | Anti-tumor agent |
| WO2009023846A2 (en) | 2007-08-15 | 2009-02-19 | The Research Foundation Of State University Of New York | Methods for heat shock protein dependent cancer treatment |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| CN102573486A (zh) | 2009-06-08 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| CN108752280A (zh) * | 2009-08-17 | 2018-11-06 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
| CA2890748A1 (en) * | 2012-11-13 | 2014-05-22 | Memorial Sloan-Kettering Cancer Center | Indole compounds and their use as antimicrobials |
| AU2015259173B2 (en) * | 2014-05-13 | 2019-09-05 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
| ES2824576T3 (es) * | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| WO2017049295A1 (en) * | 2015-09-18 | 2017-03-23 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
-
2015
- 2015-05-13 AU AU2015259173A patent/AU2015259173B2/en not_active Ceased
- 2015-05-13 EA EA201692155A patent/EA201692155A1/ru unknown
- 2015-05-13 KR KR1020167034791A patent/KR102461419B1/ko active Active
- 2015-05-13 JP JP2016567656A patent/JP6607870B2/ja not_active Expired - Fee Related
- 2015-05-13 CA CA2948621A patent/CA2948621A1/en active Pending
- 2015-05-13 SG SG11201609336PA patent/SG11201609336PA/en unknown
- 2015-05-13 ES ES15727138T patent/ES2774975T3/es active Active
- 2015-05-13 MX MX2016014755A patent/MX375924B/es active IP Right Grant
- 2015-05-13 TW TW104115328A patent/TWI699204B/zh not_active IP Right Cessation
- 2015-05-13 BR BR112016026470A patent/BR112016026470A8/pt not_active Application Discontinuation
- 2015-05-13 WO PCT/US2015/030641 patent/WO2015175707A1/en not_active Ceased
- 2015-05-13 CN CN201580036973.3A patent/CN107074806B/zh not_active Expired - Fee Related
- 2015-05-13 US US15/310,142 patent/US9878987B2/en active Active
- 2015-05-13 EP EP15727138.8A patent/EP3143013B1/en active Active
-
2016
- 2016-11-07 IL IL248792A patent/IL248792B/en active IP Right Grant
- 2016-11-11 PH PH12016502244A patent/PH12016502244A1/en unknown
-
2017
- 2017-12-14 US US15/842,755 patent/US10160729B2/en active Active
-
2018
- 2018-11-02 US US16/179,155 patent/US10647683B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107074806A (zh) | 2017-08-18 |
| SG11201609336PA (en) | 2016-12-29 |
| AU2015259173B2 (en) | 2019-09-05 |
| US20170233352A1 (en) | 2017-08-17 |
| EP3143013A1 (en) | 2017-03-22 |
| IL248792A0 (en) | 2017-01-31 |
| JP6607870B2 (ja) | 2019-11-20 |
| KR102461419B1 (ko) | 2022-11-02 |
| TW201601725A (zh) | 2016-01-16 |
| WO2015175707A1 (en) | 2015-11-19 |
| MX2016014755A (es) | 2017-03-27 |
| US10160729B2 (en) | 2018-12-25 |
| AU2015259173A1 (en) | 2016-12-08 |
| US9878987B2 (en) | 2018-01-30 |
| US20180170883A1 (en) | 2018-06-21 |
| ES2774975T3 (es) | 2020-07-23 |
| EP3143013B1 (en) | 2019-12-18 |
| BR112016026470A8 (pt) | 2021-07-20 |
| CA2948621A1 (en) | 2015-11-19 |
| MX375924B (es) | 2025-03-07 |
| JP2017515857A (ja) | 2017-06-15 |
| BR112016026470A2 (pt) | 2017-08-15 |
| KR20170005095A (ko) | 2017-01-11 |
| CN107074806B (zh) | 2021-04-23 |
| US20190241526A1 (en) | 2019-08-08 |
| EA201692155A1 (ru) | 2017-04-28 |
| US10647683B2 (en) | 2020-05-12 |
| PH12016502244A1 (en) | 2017-01-09 |
| TWI699204B (zh) | 2020-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247847B (en) | ror gamma modulator and their use | |
| IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| EP3148729A4 (en) | Hydride-coated microparticles and methods for making the same | |
| GB201400428D0 (en) | Provisioning apparatus and methods therefor | |
| SI3215147T1 (sl) | Nevroatenuacijske spojine norketamina in postopki | |
| EP3173967A4 (en) | Secure interaction method and device | |
| GB201405246D0 (en) | System and apparatus | |
| EP3155399A4 (en) | Viscometer and methods for using the same | |
| PT3166636T (pt) | Moduladores de psgl-1 e utilizações dos mesmos | |
| SG11201704473WA (en) | New methods and uses | |
| GB201603311D0 (en) | New uses and methods | |
| IL251107A0 (en) | Compounds and methods | |
| GB201417185D0 (en) | Apparatus and methods | |
| GB201612858D0 (en) | New uses and methods | |
| GB201405243D0 (en) | System and apparatus 1 | |
| IL248792B (en) | hsp70 modulators and methods for their preparation and use | |
| IL251335A0 (en) | Piperidinylpyrazolopyrimidinones and their use | |
| GB2548839B (en) | New uses and methods | |
| PL3122571T3 (pl) | Sposób i system złocenia | |
| GB201405715D0 (en) | Methods, apparatus and materials | |
| GB201517786D0 (en) | Methods and materials | |
| GB201408091D0 (en) | Methods and uses | |
| EP3120724A4 (en) | Detachable structure and object comprising same | |
| PL3134581T3 (pl) | Sposób i środek do stabilizacji gruntu | |
| GB201416082D0 (en) | Method and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |